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Abstract
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a
significant liver disease, and it covers the disease spectrum from simple steatosis
with a risk of development of non-alcoholic steatohepatitis (NASH) to fibrosis,
subsequent cirrhosis, end-stage liver failure, and liver cancer with a potential
need for liver transplantation. NAFLD and NASH are closely related to obesity,
metabolic syndrome, and type 2 diabetes (T2D). The role of gut hormones,
especially glucagon-like peptide 1 (GLP-1), is important in NAFLD. Bariatric
surgery has the potential for inducing great weight loss and may improve the
symptoms of metabolic syndrome and T2D. Recent data demonstrated significant
effects of bariatric surgery on GLP-1 and other gut hormones and important lipid
metabolic and inflammatory abnormalities in the pathophysiology of NAFLD.
Therefore, bariatric surgery may reverse the pathological liver changes in
NAFLD and NASH patients. In the present review, we describe NAFLD and
NASH pathophysiology and the primary effects of bariatric surgery on metabolic
pathways. We performed a systematic review of the beneficial and harmful
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effects and focused on changes in liver disease severity in NAFLD and NASH
patients. The specific focus was liver histopathology as assessed by the invasive
liver biopsy. Additionally, we reviewed several non-invasive methods used for
the assessment of liver disease severity following bariatric surgery.
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Core tip: Non-alcoholic fatty liver disease (NAFLD) is a significant liver disease with
risks of steatohepatitis (NASH), fibrosis, and cirrhosis. NAFLD and NASH are closely
related to obesity, the metabolic syndrome, and type 2 diabetes (T2D). Bariatric surgery
induces weight loss and improves the features of the metabolic syndrome and T2D.
Surgery may reverse pathological liver changes. In the present review, we focus on the
primary effects of bariatric surgery on metabolic pathways and systematically reviews
the effects of bariatric surgery on changes in liver disease severity in NAFLD and NASH
patients.
Citation: Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, Grønbæk
H. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology
to clinical effects. World J Hepatol 2019; 11(2): 138-149
URL: https://www.wjgnet.com/1948-5182/full/v11/i2/138.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i2.138
INTRODUCTION
Alarming increases in obesity and diabetes coupled with changes towards unhealthy
lifestyles and dietary habits have contributed to a dramatic increase in non-alcoholic
fatty liver  disease (NAFLD),  which affects  25%-30% of  the general  population[1].
NAFLD is most often asymptomatic and consists of a disease spectrum ranging from
simple steatosis (NAFL) and steatohepatitis (NASH) to fibrosis and cirrhosis, with
significant clinical consequences, including but not limited to ascites, varices, hepatic
encephalopathy, liver cancer and liver transplantation or early death[2]. NASH may
develop with hepatic inflammation, hepatocellular injury, macrophage and hepatic
stellate cell  activation in patients with simple steatosis.  If  untreated, NASH may
progress to cirrhosis. NASH-induced cirrhosis is fast becoming the most common
indication for liver transplantation, which is strongly associated with poor quality of
life[3].
NAFLD is closely related to obesity and type 2 diabetes mellitus (T2D), and it is
often termed the hepatic manifestation of metabolic syndrome[4,5]. The prevalence of
NASH increases with components of the metabolic syndrome in T2D[6].  Available
epidemiological data suggest a prevalence of NAFLD of 40%-70% in European T2D
patients[1]. Insulin resistance is more prevalent in NASH patients than patients with
simple steatosis[7], and patients with NAFLD without T2D exhibit decreased insulin
sensitivity[8].
Bariatric surgery is an efficient treatment of obesity and causes sustained weight
loss with potential reductions in hepatic fat, inflammation and fibrosis[9,10]. Roux-en-Y
gastric bypass surgery (RYGB) is the most effective treatment for obesity[11].  This
procedure improves glycaemic control, and T2D patients experience a reduced need
for antidiabetic medication within days after surgery[9]. Sleeve gastrectomy (SG) and
adjustable gastric banding (AGB) are alternative surgical approaches that significantly
reduce gastric volume without changing the upper gastrointestinal tract anatomy. SG
has gained popularity in recent years and been established as a comparable method to
RYGB. In contrast, AGB is associated with less weight loss than RYGB surgery. The
indication for bariatric surgery is severe obesity with or without T2D and/or other
comorbidities[9].
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LITERATURE SEARCH
We searched the following databases: MEDLINE Ovid (1946 to June 2018), Science
Citation Index Expanded (Web of Science; 1900 to June 2018), and PubMed [Bethesda
(MD): National Library of Medicine (US) 1966 to June 2018]. The following search
terms were used: “Non-alcoholic fatty liver disease” (MeSH, all  fields)  or “Non-
alcoholic steatohepatitis” (all fields) and “bariatric surgery (MeSH, all fields). Only
English language articles were selected, and case reports were excluded. Full-text
evaluation was performed, and references from relevant manuscripts were reviewed
manually for additional manuscripts. This search strategy identified 404 studies at the
end of June 2018. Studies were included in our comprehensive review if they were
published between January 2010 and June 2018, were prospective or retrospective
observational  studies  and  if  they  evaluated  the  effects  of  bariatric  surgery  on
histopathological NAFLD. In total, we ended up with 13 studies.
PATHOGENESIS OF NAFLD
The pathogenic mechanisms for the development and progression of NAFLD are
complex and multifactorial[12]  (Figure 1).  Genetic and epigenetic factors affect the
development of NAFLD and NASH progression and potentially influence or modify
risk factors[13-16]. Dietary sugars, fat, adipose tissue lipolysis, and de novo lipogenesis
contribute to increased hepatic fat influx and accumulation in obese patients[17]. Obese
patients exhibit increased adipose tissue mass, which leads to adipocyte dysfunction,
including insulin resistance, increased lipolysis and apoptosis, and results in local
inflammation  and  cytokine  release.  Insulin  resistance  reduces  insulin-induced
inhibition of lipolysis, and negatively affects the ability of the adipose tissue to store
fat, which results in increased free fatty acids in the blood. Insulin resistance induces
further insulin secretion, which instigates high blood insulin levels[18,19].
Hepatic de novo lipogenesis is also augmented in obese patients, partially due to
enzyme upregulation induced by hyperinsulinaemia, elevated plasma glucose levels
and endoplasmic reticulum (ER) stress[20-22]. Lipid accumulation in the liver primarily
consists of triglycerides, which may not be hepatotoxic per se, but reflects the general
inability of hepatocytes to handle fatty acids and leads to the concurrent accumulation
of toxic lipid metabolites[23-25]. Long-chain saturated fatty acids resulting from de novo
lipogenesis specifically harm liver cells via triggering the formation of reactive oxygen
species, which highly contribute to hepatic lipotoxicity[19].
Activation  of  death  receptors  and  their  ligands,  induction  of  ER  stress,  the
production of reactive oxygen species and mitochondrial stress and dysfunction lead
to hepatocyte injury and death with subsequent release of proteins, debris, etc., which
are collectively defined as damage-associated molecular patterns (DAMPs)[26,27]. Fatty
acids, DAMPs and pathogen-associated molecular patterns (PAMPs), e.g., bacteria
and endotoxins,  likely originating from a leaky gut,  are the primary inducers of
hepatic  inflammation,  which  involves  activation  of  resident  and  recruited
macrophages in the liver[28,29].  Macrophage activation results in pro-inflammatory
cytokine secretion and the activation of hepatic stellate cells into myofibroblasts,
which  secrete  the  collagen  that  contributes  to  extracellular  matrix  formation.
Myofibroblasts are also directly responsive to cytokines, DAMPs and PAMPs, thus
further propagating fibrosis formation[30].
METABOLIC EFFECTS OF BARIATRIC SURGERY
Bariatric surgery has tremendous effects on metabolic functions. Buchwald et al[31]
performed a meta-analysis of 136 studies that assessed the impact of bariatric surgery
on metabolic outcomes and reported a complete resolution of T2D in more than 75%
of diabetic patients and an excessive weight loss of almost 60%. A review of key
results from the Swedish Obese Subjects study reported a 72% remission rate of T2D
two years post-bariatric surgery[32]. Several other studies demonstrated that RYGB and
SG were superior to conventional pharmacological therapy in achieving glycaemic
control in T2D patients[33-35].
NAFLD is closely associated with obesity and T2D, and the mechanisms implicated
in improving obesity and T2D following bariatric surgery likely play important roles
in the resolution of NAFLD. Several mechanisms independent of weight loss are
involved  in  the  initial  metabolic  responses  to  RYGB  and  SG  procedures  and
maintaining these improvements over the long term, despite the obvious causality
between weight loss and improvements in T2D and NAFLD.
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Figure 1
Figure 1  Risk factors and mechanisms associated with non-alcoholic fatty liver disease development and
progression. NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; ER: Endoplasmic
reticulum; ROS: Reactive oxygen species; HCC: Hepatocellular carcinoma.
The almost immediate metabolic benefits of bariatric surgery, independent of any
significant  weight  loss,  have  been  known  for  decades [36 ]  but  are  striking
nonetheless[31,37,38]. Three primary mechanisms are involved in the improved glycaemic
control associated with the RYGB and SG procedures: (1) early improved hepatic
insulin  sensitivity  due  to  the  post-surgery  calorie  restriction;  (2)  late  improved
peripheral insulin sensitivity due to weight loss;  and (3) improved post-prandial
insulin secretion due to a rise in glucagon-like peptide 1 (GLP-1) secretion (Figure 2).
Several studies investigated the post-surgical metabolic changes, and whether the
change in the release of gut hormones or surgery-induced restriction of food intake
provides the essential effects on glycaemic control remains controversial. Jørgensen et
al[38,39] found an increase in post-prandial GLP-1, insulin secretion and hepatic insulin
sensitivity within days after RYGB, and this increase was sustained for at least 1 year
in diabetic and non-diabetic-matched subjects, which is consistent with other RYGB
and SG studies[37,40,41]. The GLP-1 increase represents a powerful beta-cell stimulus and
is  explained  by  the  accelerated  entry  of  nutrients  into  the  small  intestine  after
RYGB[42,43]  and  SG[44],  which  increases  the  glucose  absorption  rate  in  the  L  cells
responsible for the GLP-1 secretion[45]. The accelerated transport of nutrients into more
distal parts of the small intestine may further explain the exaggerated GLP-1 response
because a higher density of L cells are found in this area[46]. Notably, GLP-1 may have
beneficial gene-regulatory effects on fatty acid oxidation and insulin sensitivity in
hepatocytes[47],  but  these findings require  confirmation in humans.  Postprandial
glucagon responses also increase post-operatively[38,48] despite the inhibitory effects of
GLP-1 on glucagon secretion[39]. This paradoxical effect (in the context of improved
glucose  metabolism)  may  represent  gut-derived  glucagon[42]  and  may  exert  an
attenuating effect on glycaemic control post-surgery.
Steven et al[49],  among others[50],  demonstrated that the reduced liver fat content
from calorie restriction explained the early improvement in hepatic insulin sensitivity,
as illustrated using magnetic resonance imaging. These data suggest that significant
caloric restriction explains the almost immediate metabolic benefits from bariatric
surgery due to improved liver function[49,51].  Vetter et  al[48]  demonstrated that the
improvements in liver insulin sensitivity from RYGB exceeded lifestyle modifications.
However,  blockade  of  the  GLP-1  receptor  using  the  antagonist  exendin9–39
consistently lowered insulin secretion after RYGB and SG[39,52],  and it reversed the
postprandial hyperinsulinaemic hypoglycaemia observed post-operatively[38], which
confirmed the causative role of GLP-1 in beta-cell stimulation[53-55]. Calorie restriction
is the leading mechanism of the early metabolic changes after bariatric surgery, but
the  gut  hormones,  particular  GLP-1,  remain  crucial  for  the  fine-tuning  of  the
glycaemic control and post-prandial insulin secretion[56].
A  hyperinsulinaemic  clamp study of  Bojsen-Møller  et  al[37]  demonstrated that
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Figure 2
Figure 2  Main metabolic effects of bariatric surgery on remission. NAFLD: Non-alcoholic fatty liver disease.
peripheral insulin sensitivity, as assessed using glucose disposal and suppression of
fatty acids, increased after three months in relation to the surgery-induced weight
loss. Lifestyle modifications exert the same powerful effects on glycaemic control and
NAFLD[48,57],  but this intervention generally fails to sustain the short-term weight
loss[32]. Notably, bariatric surgery is superior in maintaining calorie restriction and
long-term weight loss, which is facilitated at least partially by the reduced appetite
observed post-operatively[58,59]. The long-term reduced appetite may be attributable to
a favourable shift in the anorectic gut hormones GLP-1 and peptide-YY (PYY)[58,60]. An
antagonist study using exendin9–39 and a dipeptidyl peptidase 4 (DPP-4) inhibitor
(blocking the DPP-4-mediated formation of active PYY from its precursor) in RYGB-
operated subjects demonstrated a 20% increase in food intake[61]. Several other factors
are  candidates  for  the  long-term  metabolic  improvements  of  bariatric  surgery,
including  ghrelin[62],  adiponectin[63],  increased  plasma bile  acids[64]  and  changed
intestinal  microbiota[65],  but  proof  of  causality  for  these  factors  remains  to  be
established in humans.
HEPATIC EFFECTS OF BARIATRIC SURGERY
Bariatric surgery affects NAFLD not only through a rapid and substantial weight loss
but also via simultaneous effects on important lipid metabolic and inflammatory
pathways  involved in  NAFLD pathophysiology[66,67].  Bariatric  surgery  promotes
changes  in  three  crucial  metabolic  areas  influencing NAFLD:  improved glucose
homeostasis, improved lipid metabolism and reduced inflammatory activity (Figure
2). These effects are followed by significant effects on liver abnormalities in NAFLD
and NASH patients.
Liver histology
A systematic review and meta-analysis[68] in 2008 assessed the histological effects of
bariatric  surgery in NAFLD patients.  This  review concluded that  the features of
steatosis, steatohepatitis, and fibrosis improve or resolve in most patients following
weight loss after bariatric surgery. A Cochrane review in 2010 reported more discrete
conclusions[69]. These authors were not able to identify any randomized clinical trials
at that time and advised caution even though several reports demonstrated potential
favourable effects of bariatric surgery. Most studies reported beneficial effects on
steatosis, and more than half of the studies demonstrated significant improvements in
histological inflammation. Six studies demonstrated improvement in fibrosis scores,
but 4 studies[70-73] reported some worsening of fibrosis.
Our  literature  search  did  not  identify  any  randomized  controlled  trials  that
assessed the hepatic histological effects of bariatric surgery in NAFLD patients. We
performed a comprehensive review of prospective and retrospective observational
studies  published  since  2010  to  evaluate  the  effects  of  bariatric  surgery  on
histopathological  NAFLD (Table 1).  We identified 13 studies:  Eight studies with
prospective designs,  two studies with retrospective designs and three studies in
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which the design was not obvious. The types of surgery included RYGB, AGB and SG,
and most studies assessed the effect of RYGB. The sample size ranged from 9 to 578
patients. The studies clustered into three categories based on participant numbers:
Two large studies with more than 150 participants[74,75],  three studies with 50-150
participants[10,76,77] and eight small studies with less than 50 participants[78-85].
In the largest study by Caiazzo et al[74] including more than 500 patients, the effects
of  RYGB  and  AGB  were  compared.  Improvement  and  resolution  of  steatosis,
inflammation and fibrosis  were  observed one and five  years  after  both types  of
surgery. Biopsies at all three time points (before and 1 and 5 years post-surgery) were
available in 315 patients, and the authors did not describe any cases of worsening. The
best effects on weight loss and liver histology were achieved in the RYGB patients,
and the primary effect derived from a greater weight loss but additionally explained
by a more positive influence on glucose and lipid metabolism.
The second largest study of 160 patients undergoing RYGB or ABG with a mean
follow-up  of  31  mo  demonstrated  resolution  or  improvement  of  steatosis  and
inflammation in most patients[75]. Fibrosis resolved or improved in more than half of
the patients. However, 8% of the patients progressed or developed steatosis de novo
after surgery. Portal inflammation worsened in 10% and developed de novo in 27% of
the  patients,  and  16%  developed  lobular  inflammation  after  surgery.  Fibrosis
progressed  in  12%  of  the  patients  with  pre-surgery  fibrosis  and  another  21%
developed de novo fibrosis. Three patients developed NASH de novo after surgery.
In  general,  all  of  the  smaller  studies  reported  improvements  in  steatosis,
inflammation and fibrosis. However, three of these studies found a worsening of
some histological  features,  e.g.,  inflammation[79]  and fibrosis[77,81],  and three other
studies  reported  no  worsening[76,78,80].  The  remaining  studies  did  not  describe
worsening in any patients. The histological liver changes were accompanied with
beneficial  effects  on  metabolic  syndrome[78,79],  hypertension,  dyslipidaemia  and
obstructive sleep apnoea[84]. Most studies performed follow-up biopsies after one year
or later  after  surgery,  but two studies performed follow-up at  three[83]  and six[80]
months. Notably, the effects of surgery were visible at these time points, even for
fibrosis.
Lassailly et al[10] investigated differences in patients with resolution of NASH one
year after surgery and patients with persistent NASH and found that these patients
had  lost  significantly  less  weight  and  were  more  frequently  classified  with  a
refractory IR profile, which suggests that the weight loss was of primary importance.
Non-invasive methods
Other studies used diverse non-invasive methods to examine the hepatic effects of
bariatric surgery and found improvements in general. Several studies investigated
how bariatric surgery affected the levels of circulating liver transaminases, in general
reporting  favourable  effects,  as  summarized  in  a  meta-analysis[86].  However,
transaminases exhibit limited accuracy for the prediction of NASH severity.
Several  studies  used  non-invasive  fibrosis  scores.  One  study  demonstrated
decreases  in  NAFLD fibrosis  scores,  ratio  of  aminotransferase  (AST)  to  alanine
aminotransferase (ALT), AST-to-platelet ratio index (APRI), and BARD score (BMI,
ASAT/ALAT ratio, and the presence of T2D) one year after surgery[87]. Decreases in
the NAFLD fibrosis score were confirmed in several other studies. Two studies of
RYGB found a significant decrease 12 mo[88] and 36 mo after surgery[89], but higher
levels in patients who regained weight after the initial weight loss. One study of 56
adolescents described a decrease in NAFLD fibrosis score one and two years after
AGB[90]. However, Simo et al[91] questioned the feasibility of the NAFLD fibrosis score
in relation to RYGB because several patients were wrongly classified or ended in a
group of indeterminate classification. None of these studies included pre- or post-
surgery biopsies as golden standards for treatment effects.
Forty-two patients who underwent diverse types of surgery were followed up with
liver  stiffness  measurements  and controlled attenuation parameter  (CAP)  using
transient elastography. Liver stiffness declined from 8.6 to 6.0 kPa one year after
surgery. CAP values declined from 322 dB/m at baseline to 251 dB/m at one year.
These changes paralleled the histological changes in 32 of the patients[85]. The decrease
in liver stiffness was consistent with a decrease from 6.95 to 5.37 kPa in another study
of 38 patients after bariatric surgery[92]. Another study of 100 prospectively included
bariatric patients reported a decrease from 12.9 to 7.1 kPa[87].
Magnetic resonance imaging (MRI) is increasingly used in the assessment of liver
pathology. A prospective study of 31 obese patients undergoing RYGB demonstrated
a significant reduction in hepatic fat content using MRI spectroscopy 12 mo after
surgery[93]. A decrease in the liver fat fraction using MRI was also observed six[94] and
12 mo[95] after surgery in other studies. These results were supported by a decreased or
complete resolution of liver steatosis/NAFLD on ultrasonography one to five years
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Table 1  Recent studies (2010-) with histological assessment of liver biopsies at follow-up
Ref. Design Patients withfollow-up
Surgical inter-
vention Steatosis Inflammation Fibrosis
Any cases of
worsening
Mean/median
follow-up in
months
Weiner et
al[76], 2010
Missing 116 RYGB, AGB,
BPD-DS
Improved, 70%
complete
resolution
Improved, 86%
complete
resolution
Improved No 19.4 (± 8.3)
Moretto et
al[77], 2012
Retrospective 78 Gastric bypass Improved Improved
ballooning, 55%
complete
resolution of
NASH
Trend for
improvement
Yes Unknown
Vargas et al[78],
2012
Prospective 26 RYGB Improved Improved, 84%
complete
resolution of
NASH
Improved No 16 (± 3)
Tai et al[79],
2012
Prospective 21 RYGB Improved, 95%
complete
resolution
Improved,
100% complete
resolution of
NASH
Improved Yes 12
Caiazzo et
al[74], 2014
Prospective 578 (1 yr), 413
(5 yr)
RYGB, AGB Improved Improved Improved NA 12 and 60
Lassailly et
al[10], 2015
Prospective 82 Gastric bypass,
AGB, SG, PBD-
DS
Improved Improved, 85%
complete
resolution of
NASH
Improved NA 12
Praveen et
al[80], 2015
Prospective 30 RYGB, SG Improved in
97%
Improved in
46%
Improved in
46%
No 6
Taitano et
al[75], 2015
Missing 160 RYGB, AGB Improved,
complete
resolution in
73%
Improved, 88%
complete
resolution of
NASH
Improved, 53%
complete
resolution
Yes 31 (± 26)
Schneck et
al[81], 2016
Missing 9 RYGB Improved in all
patients
Improved in all
patients
Improved Yes 55 (44-75)
Froylich et
al[82], 2016
Retrospective 25 RYGB, SG Improved Improved Trend for
improvement
NA 18
Aldoheyan et
al[83], 2017
Prospective 27 SG Improved Improved Improved NA 3
Manco et al[84],
2017
Prospective 20 SG (n = 20) vs
IGWLD, NSWL
Improved Improved,
100% complete
resolution of
NASH
Improved NA 12
Garg et al[85],
2018
Prospective 32 RYGB, AGB,
SG
Improved Improved Improved NA 12
RYGB: Roux-en-Y gastric bypass; AGB: Adjustable gastric banding; BPD-DS: Biliopancreatic diversion with duodenal switch; SG: Sleeve gastrectomy;
IGWLD: Intragastric weight loss device; NSWL: Nonsurgical weight loss; NA: Not assessed.
after SG[96,97]. A decrease in hepatic left lobe volume on ultrasound was also observed
after two years in 75 women who underwent laparoscopic AGB[98]. Two small studies
found improvements in liver damage and NAFLD using ultrasound imaging[99] and
CT[100].
Additional exploratory results include decreased serum levels of the hepatocyte
apoptosis marker cytokeratin (CK)-18 one year after surgery in nine patients, which
was maintained approximately four years later with corresponding improvements in
liver histology[81]. Significant improvements in metabolic liver function capacity using
LiMAx, which is based on hepatic 13C-methacetin metabolism by cytochrome P450
1A2, were also observed six and 12 mo after surgery[101].
Liver-related mortality
Overall, current studies reported no significant effects on liver-related mortality after
bariatric  surgery,  but  larger long-term follow-up studies are necessary to firmly
establish the effect of bariatric surgery on liver-related mortality. A recent nation-wide
study of patients after bariatric surgery observed no increase in all-cause mortality
compared with the general population. However, there was an increased mortality
rate ratio 2.01 (95%CI: 1.06-3.84) for gastrointestinal and liver diseases, including
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peritonitis  and intestinal  obstruction[102].  Mortality  was  significantly  reduced in
patients undergoing bariatric surgery compared to a propensity-score matched cohort
of obese patients,  but there was no difference in survival when the analysis was
restricted  to  include  NASH  patients  only [103].  Liver  cirrhosis  is  a  relative
contraindication to bariatric surgery. However, no increased risks of postoperative
complications or cirrhosis-related complications were observed in 13 cirrhosis patients
undergoing SG with a follow-up of 18 mo. Weight loss in the cirrhosis patients was
comparable to the non-cirrhotic patients[104].
CONCLUSION
In conclusion, bariatric surgery has the potential to induce great weight loss and
improve the features  of  metabolic  syndrome and T2D.  Recent  data  demonstrate
significant  effects  of  bariatric  surgery  on  GLP-1  and  other  gut  hormones  and
important  lipid  metabolic  and  inflammatory  abnormalities  involved  in  the
pathophysiology of NAFLD. Therefore, bariatric surgery may reverse the pathological
liver changes in NAFLD and NASH patients. Several cohort studies demonstrated
improvements  in  NASH  histology,  but  some  studies  reported  worsened  liver
histology after  bariatric  surgery.  No studies  demonstrated reduced liver-related
mortality.
Large  randomized  clinical  trials  with  long-term  follow-up  are  needed  to
demonstrate the beneficial effects of bariatric surgery and identify a definitive role of
bariatric surgery in NASH patients.
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